The aim of this work was to evaluate whether the effect of neoadjuvant pertuzumab combined with trastuzumab in comparison with trastuzumab alone varies as a function of PAM50-defined intrinsic subtypes in a real-world cohort of patients with HER2-positive early breast cancer. Here, ERBB2 is linked to breast cancer.